Karvonen, Hanna <br/><br/>
Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.  [electronic resource] 

 -  Oncogene  04 2019 
 - 3288-3300 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/s41388-018-0670-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aniline Compounds--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Bridged Bicyclo Compounds, Heterocyclic--pharmacology<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm--genetics<br/>Humans<br/>Oncogene Proteins, Fusion--genetics<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Proto-Oncogene Proteins c-bcl-2--genetics<br/>Receptor Tyrosine Kinase-like Orphan Receptors--genetics<br/>Sulfonamides--pharmacology<br/>Survival Rate<br/>Translocation, Genetic--drug effects<br/>Up-Regulation--drug effects<br/>Wnt Signaling Pathway--drug effects<br/>Wnt-5a Protein--genetics<br/>rhoA GTP-Binding Protein--genetics